Antifungal drug therapy in avian species

Veterinary Clinics of North America - Exotic Animal Practice

Volumn 6, Issue 2, 2003, Pages 337-350

  Orosz, Susan E ^a  

^a AniMed Research Consulting LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCD; ALLYLAMINE DERIVATIVE; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; CASPOFUNGIN; CLOTRIMAZOLE; CYCLOSPORIN; CYTOSINE DERIVATIVE; DEOXYCHOLATE SODIUM; ECHINOCANDIN DERIVATIVE; ENILCONAZOLE; FLUCONAZOLE; FLUCYTOSINE; FLUOROPYRIMIDINE DERIVATIVE; IMIDAZOLE DERIVATIVE; ITRACONAZOLE; KETOCONAZOLE; MACROLIDE; MICONAZOLE; NEW DRUG; NYSTATIN; POLYENE ANTIBIOTIC AGENT; POSACONAZOLE; PYRROLE DERIVATIVE; TERBINAFINE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORICONAZOLE;

ASPERGILLOSIS; BIRD DISEASE; CANDIDIASIS; COCCIDIOIDOMYCOSIS; DERMATOMYCOSIS; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG RELEASE; DRUG SAFETY; DRUG SCREENING; DRUG SOLUBILITY; DRUG STORAGE; DRUG TISSUE LEVEL; DRUG TRANSPORT; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MUCORMYCOSIS; MYCOSIS; NONHUMAN; OPPORTUNISTIC INFECTION; REVIEW; SYSTEMIC MYCOSIS;

AVES;

EID: 0037672789     PISSN: 10949194     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1094-9194(03)00008-2     Document Type: Review

References (52)

1. Meis JFGM, Vertweij PE. Current management of fungal infections. Drugs 2002;61(Suppl 1):13-25.
2. King AS, McClelland J. Integument. In: Birds: their structure and function. 2nd edition. London: Ballière Tindall; 1984. p. 23-42.
3. Orosz SE. Overview of aspergillosis: pathogenesis and treatment options. Seminars in Avian and Exotic Pet Medicine 2000;9:59-65.
4. Lewis RE, Kontoyiannis DP. Rationale for combination antifungal therapy. Pharmacotherapy 2001;21:149S-64S.
5. Singh N. Changing spectrum of invasive candidiasis and its therapeutic implications. Clinical Microbiology and Infection 2001;7(Suppl 2):1-7.
6. Rangel-Frausto MS, Wiblin T, Blumbery HM, et al. Variation in rates of Candida bloodstream infection in seven surgical ICUs and six neonatal ICUs. Clin Infect Dis 1999;29:253-8.
7. Gurwith M. Clinical efficacy of Amphotericin B colloidal dispersion against infectious caused by Aspergillus spp. Chemotherapy 1999;45(Suppl 1):34-8.
8. Kontoyiannis DP, Lewis RE. Antifungal drug resistance of pathogenic fungi. Lancet 2002;30;359(9312):1135-44.
9. Orosz SE, Frazier DL. Antifungal agents: a review of their pharmacology and therapeutic indications. Journal of Avian Medicine and Surgery 1995;9:8-18.
10. Herbrecht R, Letscher V, Andres E, Cavalier A. Safety and efficacy of Amphotericin B colloidal dispersion. Chemotherapy 1999;45(Suppl 1):67-76.
11. Mitrano FP, Outman WR, Baptista RJ, et al. Chemical and visual stability of Amphotericin B in 5% dextrose injection stored at 4°C for 35 days. American Journal of Hospital Pharmacy 1991;48:2635-7.
12. Edmonds LC, Davidson L, Bertino JS Jr. Solubility and stability of Amphotericin B in human serum. Ther Drug Monit 1989;11:323-6.
13. Plotnick AN. Lipid-based formulations of Amphotericin B. J Am Vet Med Assoc 2000;216:838-41.
14. Boswell GW, Buell D, Bekersky I. AmBisome (liposomal Amphotericin B): a comparative review. J Clin Pharmacol 1998;38:583-92.
15. Myint H. AmBisome: an overview of current use. Hosp Med 1999;60:123-6.
16. Ringen O, Meunier F, Tollemar J, et al. Efficacy of Amphotericin B encapsulated in liposomes (Ambisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother 1991;28:73-81.
17. Maschmeyer G. New antifungal agents-treatment standards are beginning to grow old. J Antimicrob Chemother 2002;49:239-41.
18. Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998;26:1383-6.
19. Fraser SL, Rowles DM. Amphotericin B lipid complex (ABLC)-associated hypertension: case report and review. Clin Infect Dis 1999;29:1564-5.
20. De Marie S, Jan Knegt R, Bakker-Woodenberg IAJM. Clinical use of liposomal and lipid-complexed Amphotericin B. J Antimicrob Chemother 1994;33:907-16.
21. Mullen AB, Carter KC, Baille AJ. Comparison of the efficacies of various formulations of Amphotericin B against murine visceral leishmaniasis. Antimicrob Agents Chemother 1997;41:2089-92.
22. Clemons KV, Stevens DA. Comparison of Fungizone Amphotec, AmBisome, and Abelcet for treatment of systemic murine cryptococcosis. Antimicrob Agents Chemother 1998;42:899-902.
23. Vandermast H, Dorrestein GM, Westerhof J. A fatal treatment of sinusitis in an African grey parrot. Journal of the Association of Avian Veterinarians 1990;4:189.
24. Redig PT, Duke GE. Comparative pharmacokinetics of antifungal drugs in domestic turkeys, red-tailed hawks, and great-horned owls. Avian Dis 1988;29:649-61.
25. Gigolashvili T. Update on antifungal therapy. Cancer Practice 1999;7:157-9.
26. Andes D, van Ogtrop M. In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model. Antimicrob Agents Chemother 2000;44:938-42.
27. Groll AH, Piscitelli SC, Walsh TJ. Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo. Pharmacotherapy 2001;21:133S-485S.
28. Grant SM, Clissold SP. Fluconazole: a review of it pharmacodynamic and pharmacokinetic properties and therapeutic use in superficial and systemic mycoses. Drugs 1990;139:877-916.
29. Grant SM, Clissold SP. Itraconazole: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in superficial and systemic mycoses. Drugs 1989;37:310-44.
30. De Nollin S, Van Belle H, Goossens F, et al. Cytochemical and biochemical studies of yeasts after in vitro exposure to miconazole. Antimicrob Agents Chemother 1977;11:500-13.
31. Berenguer J, Ali NM, Allende MC. Itraconazole for experimental pulmonary aspergillosis: comparison with Amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasma. Antimicrob Agents Chemother 1994;38:1303-8.
32. Warnock DW, Turner A, Burke J. Comparison of high-performance liquid chromatographic and microbiological methods for determination of itraconazole. J Antimicrob Chemother 1988;21:93-100.
33. Orosz SE, Schroeder EC, Cox SK, et al. The effects of formulation on the systemic availability of itraconazole in pigeons. Journal of Avian Medicine and Surgery 1995;9:255-62.
34. Jones MP, Orosz SE, Cox SK, Frazier DL. Pharmacokinetic disposition of itraconazole in red-tailed hawks (Buteo jamaicensis). Journal of Avian Medicine and Surgery 2000; 14:15-22.
35. Orosz SE, Frazier DL, Schroeder EC, et al. Pharmacokinetic properties of itraconazole in blue-fronted Amazon parrots (Amazona aestiva aestiva). Journal of Avian Medicine and Surgery 1996;10:168-73.
36. Perelman B, Smith B, Bronstein D, et al. Use of azole compounds for the treatment of experimental aspergillosis is turkey. Avian Pathology 1992;21:591-9.
37. Boogaerts MA, Verhoef GE, Zachee P, et al. Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses 1989;32:103-8.
38. Morganstern GR, Prentice AG, Prentice HG, et al. A randomized controlled trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with haematological malignancies. Br J Haematol 1999;105:901-11.
39. Harousseau JL, Dekker AW, Stamatoullas-Bastard A, et al. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized double-blind double placebo, multicenter trial comparing itraconazole and Amphotericin B. Antimicrob Agents Chemother 2000; 44:1887-93.
40. Meis JFGM, Verweij PE. Current management of fungal infections. Drugs 2001;61:13-25.
41. Groll AH, Walsh TJ. Antifungal triazoles. In: Yu VL, Merigan TC, Barriere SL, editors. Antimicrobial chemotherapy and vaccines. Baltimore: Williams & Wilkins; 1998. p. 1158-70.
42. Klepser ME, Wolfe EJ, Jones RN, et al. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Antimicrob Agents Chemother 1997;41:1392-5.
43. Sohnle PG, Hahn BL, Erdmann MD. Effect of fluconazole on viability of Candida albicans over extended periods of time. Antimicrob Agents Chemother 1996;40:2622-5.
44. Flammer K. Fluconazole in psittacine birds. Proceedings of the Association of Avian Veterinarians, Tampa FL; 1996. p. 203-4.
45. Garcia MT, Llorente MT, Lima JE, et al. Activity of voriconazole: postantifungal effect, effects of low concentrations and of pretreatment on the susceptibility of Candida albicans to leucocytes. Scand J Infect Dis 1999;31:501-4.
46. Tkacz JS, DiDomenico B. Antifungals: what's in the pipeline. Current opinion. Microbiology 2001;4:540-5.
47. Hajdu R, Thompson R, Sundelof JG, et al. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrob Agents Chemother 1997;41:2339-44.
48. Petraitis V, Petratiene R, Groll AH, et al. Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 1998; 42:2898-905.
49. Belani SK, Xu X, Arison BH, et al. Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine. Drug Metab Dispos 2000;28:1274-8.
50. Pérez A. Terbinafine: broad spectrum of indications in several subcutaneous and system and parasitic disease. Mycoses 1999;42:111-4.
51. Schiraldi G, Colombo D. Potential use of terbinafine in the treatment of aspergillosis. Rev Contemporary Pharmacotherapies 1997;8:349-56.
52. Dahlhausen R, Lindstrom JG, Radabaugh CS. The use of terbinafine hydrochloride in the treatment of avian fungal disease. Proceedings of the Association of Avian Veterinarians, Portland; 2000. p. 35-9.